Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies
16441
post-template-default,single,single-post,postid-16441,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

Home > Blogs  > Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

26 Mar Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

Posted at 10:59h in Blogs by

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et al. The lancet Oncology March 14, 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6913402413664104448

 

No Comments

Sorry, the comment form is closed at this time.